Dolzhenko, Anton V.; Dolzhenko, Anna V.; Chui, Wai-Keung, Heterocycles, 2007, vol. 71, # 2, p. 429 - 436
作者:Dolzhenko, Anton V.、Dolzhenko, Anna V.、Chui, Wai-Keung
DOI:——
日期:——
A Triazolotriazine‐Based Dual GSK‐3β/CK‐1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition
作者:Sara Redenti、Irene Marcovich、Teresa De Vita、Concepción Pérez、Rita De Zorzi、Nicola Demitri、Daniel I. Perez、Giovanni Bottegoni、Paola Bisignano、Maicol Bissaro、Stefano Moro、Ana Martinez、Paola Storici、Giampiero Spalluto、Andrea Cavalli、Stephanie Federico
DOI:10.1002/cmdc.201800778
日期:2019.2.5
which could help in the development of more potent covalent inhibitors of GSK-3β. Preliminary studies on in vitro models of Parkinson's disease revealed that compound 12 is not cytotoxic and shows neuroprotective activity. These results encourage further investigations to validate GSK-3β/CK-1δ inhibition as a possible new strategy to treat neuroinflammatory/degenerative diseases.
energetic compounds 3-nitro-[1,2,4] triazolo [5,1-c] [1,2,4] triazine-4-amine (2) and N-(7-amino-[1,2,4] triazolo [1,5-a] [1,3,5] triazine-5-yl)nitramide (4) were prepared by the simple and straightforward synthesis from the commercially available 3-amino-1,2,4-triazole. The derivatives 5–8 from 4 were prepared to reduce the acidity and improve the detonation performance. All the compounds were fully